Jai Radhakrishnan, MD, discusses why IgG4-related kidney disease is often missed and what MITIGATE subgroup data presented at ASN Kidney Week 2026 show
Commentary|Articles|March 4, 2026
The Oncology Pharmacist Advocacy Tool Kit: Real-World Scripts, Hill Day Strategies, and Policy Insights
Fact checked by: Kirsty Mackay
LeAnne Kennedy, PharmD, BCOP, CPP, FHOPA, FASTCT, discusses the importance of advocacy for oncology pharmacists in both patient care and professional recognition. She highlights practical ways pharmacists can advocate—such as refining an elevator pitch, participating in virtual Hill Days, and partnering with professional organizations such as ASHP and HOPA.
Advertisement
Advertisement
Pharmacy Times: In your Policy & Practice presentation at Tandem, you focused on the oncology pharmacist’s role in shaping cancer care through advocacy. What were some key messages you hoped attendees would take away from your session?
Related to this article
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Phase 3 data show pembrolizumab beats chemotherapy, offering durable first-line control with fewer severe toxicities and chemo-free potential.
In an interview with Pharmacy Times, Danielle Roman, PharmD, BCOP, FHOPA, discusses NCCN breast cancer guideline updates involving ESR1 mutation testing, targeted therapies, and pharmacists’ roles in monitoring, patient counseling, and treatment access.
Specialty pharmacy liaisons improve breast cancer care by easing access barriers, managing side effects, boosting adherence, and navigating new therapies and policies.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association discusses pharmacists’ role in diabetes and CKD care from ASN Kidney Week 2026
Pharmacists can support effective cancer pain treatment by starting constipation prevention with opioid therapy and reassessing bowel function before symptoms become a barrier to care.
Six-year NATALEE data show adjuvant ribociclib (Kisqali) plus endocrine therapy improves overall survival in high-risk HR+/HER2- early breast cancer, with pharmacist-led monitoring.
Advertisement
Advertisement